Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Review Article Volume 3 Issue 11

A Review of Ongoing Trials to Treat COVID-19

Anirban Adhikary1*, Kakoli Halder1, Debmalya Ghosh1, Snehansu Biswas2, Indranil Chatterjee2 and Suman Kumar Nath2

1B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India

*Corresponding Author: Anirban Adhikary, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Received: August 27, 2020; Published: October 15, 2020

×

Abstract

  The SARS-CoV-2 infection rose in December 2019 and afterward spread quickly around the world, especially to China, Japan and South Korea. Researchers are attempting to discover antivirals explicit to the infection. Some drugs Such as arbidol, chloroquine, remdesivir and favipiravir are right as of now experiencing clinical evaluations to test their sensibility and security in the treatment of coronavirus disease 2019 (COVID-19) in China, some consoling results have been developed up until now. This article sums up specialists with expected viability against SARS-CoV-2..

Keywords: Chloroquine; Pneumonia; COVID-19; SARS-CoV-2; Pandemic; Out Break; Antivirals

×

References

  1. Update on the prevalence and control of novel coronavirus-induced pneumonia as of 24:00 on February 21 (2020).
  2. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 6th edition (2020).
  3. Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 5th edition (2020).
  4. Stockman LJ., et al. “SARS: Systematic review of treatment effects”. PLOS Medicine 3 (2006): e343.
  5. Su B., et al. “Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1- infected patients in a tertiary care hospital in Beijing, China”. Frontiers in Pharmacology 10 (2019): 1472.
  6. Chu CM., et al. “Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings”. Thorax 59 (2004): 252-256.
  7. Savarino A., et al. “New insights into the antiviral effects of chloroquine”. The Lancet Infectious Diseases 6 (2006): 67-69.
  8. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro”. Cell Research (2020).
  9. News: Abidol and darunavir can effectively inhibit coronavirus (2020).
  10. Delang L., et al. “Favipiravir as a potential countermeasure against neglected and emerging RNA viruses”. Antiviral Research 153 (2018): 85-94.
  11. Furuta Y., et al. “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase”. Proceedings of the Japan Academy, Series B, Physical and Biological Sciences 93 (2017): 449-463.
  12. http://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1-867a-d5524bc59cd6.html (2020).
  13. Sheahan TP., et al. “Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV”. Nature Communications 11 (2020): 222.
  14. Holshue ML., et al. “First case of 2019 novel coronavirus in the United States”. The New England Journal of Medicine (2020).
  15. Mild/Moderate 2019-nCoV Remdesivir RCT (2020).
  16. Severe 2019-nCoV Remdesivir RCT (2020).
  17. Hoffmann M., et al. “The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells”. Bio Rxiv (2020).
  18. Coleman CM., et al. “Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion”. Journal of Virology 90 (2016): 8924-8933.
  19. Shanghai Institute of Materia Medica website, Chinese Academy of Sciences. A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University discover a group of old and traditional Chinese medicines that may be efficacious in treating the novel form of pneumonia (2020).

 

×

Citation

Citation: Anirban Adhikary., et al. “A Review of Ongoing Trials to Treat COVID-19". Acta Scientific Microbiology 3.11 (2020): 35-38.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.172

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is March 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US